ChemicalBook >제품 카탈로그 >Zanubrutinib

Zanubrutinib

Zanubrutinib 구조식 이미지

카스 번호:: 1691249-45-2

상품명:: Zanubrutinib

동의어(영문):: Zebutinib;anubrutinib;Zanubrutinib;Zanmubrutinib;Zanubtutinib AP;Zanubrutinib API;The BTK inhibitor;BGB-3111(Zanubrutinib);Zanubrutinib (BGB-3111);Zanubrutinib API & all impurites

CBNumber:: CB93361383

분자식:: C27H29N5O3

포뮬러 무게:: 471.55

MOL 파일:: 1691249-45-2.mol

속성

안전

용도

공급 업체 110

Zanubrutinib 속성

끓는 점: 713.4±60.0 °C(Predicted)

밀도: 1.33±0.1 g/cm3(Predicted)

저장 조건: Store at -20°C

용해도: DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM)
Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM)

물리적 상태: 고체

산도 계수 (pKa): 15.35±0.40(Predicted)

안전

위험 및 안전 성명
위험 및 사전주의 사항 (GHS)

그림문자(GHS):

신호 어:

Warning

유해·위험 문구:

암호	유해·위험 문구	위험 등급	범주	신호 어	P- 코드
H302	삼키면 유해함	급성 독성 물질 - 경구	구분 4	경고	P264, P270, P301+P312, P330, P501
H315	피부에 자극을 일으킴	피부부식성 또는 자극성물질	구분 2	경고	P264, P280, P302+P352, P321,P332+P313, P362
H319	눈에 심한 자극을 일으킴	심한 눈 손상 또는 자극성 물질	구분 2A	경고	P264, P280, P305+P351+P338,P337+P313P
H335	호흡 자극성을 일으킬 수 있음	특정 표적장기 독성 - 1회 노출;호흡기계 자극	구분 3	경고

예방조치문구:

P261	분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P305+P351+P338	눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

NFPA 704

	0
2		0

Zanubrutinib C화학적 특성, 용도, 생산

개요

Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.

용도

Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.

신진 대사

Zanubrutinib showed a mean terminal elimination half-life of approximately 2–4 h (160 or 320 mg, QD) and an estimated oral bioavailability of 15%, relative to 3.9% (fasting state) for ibrutinib. Zanubrutinib is primarily eliminated hepatically via CYP3A4, but its metabolites have not been characterized.

Zanubrutinib 준비 용품 및 원자재

원자재

준비 용품

Zanubrutinib 공급 업체

글로벌( 110)공급 업체

공급자	전화	이메일	국가	제품 수	이점
Jinan Jianfeng Chemical Co., Ltd	0531-88110457; +8615562555968	info@pharmachemm.com	China	225	58
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32686	60
Shenzhen Nexconn Pharmatechs Ltd	+86-755-89396905 +86-15013857715	admin@nexconn.com	China	10247	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	86-571-88216897,88216896 13588875226	sales@hzclap.com	CHINA	6313	58
Chemsigma International Co., Ltd.	+86-18136843612 +86-19951791336	info@chemsigma.com	China	1229	58
Hangzhou Cherry Pharmaceutical Technology Co.,ltd	0571-81636070	info@cherrypharmatech.com	CHINA	274	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10523	58
Henan Alfa Chemical Co., Ltd	+8618339805032	alfa4@alfachem.cn	China	13040	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6393	58

Zanubrutinib 관련 검색:

Ceritinib (LDK378) Icotinib Pyrazolo[1,5-a]pyrimidine-3-carbonitrile, 4,5,6,7-tetrahydro-2-(4-phenoxyphenyl)-7-(4-piperidinyl)- 4-PHENOXYBENZOIC ACID 4-Acetyl-piperidine-1-carboxylic acid tert-butyl ester (R)-Zanubrutinib Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-2-(4-phenoxyphenyl)-7-(4-piperidinyl)-, (7S)- tert-butyl 4-(3-cyano-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile tert-butyl 4-(3-cyano-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-7-yl)piperidine-1-carboxylate Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]- Propanedinitrile, 2-[hydroxy(4-phenoxyphenyl)Methylene]- 1-Piperidinecarboxylic acid, 4-[3-(dimethylamino)-1-oxo-2-propen-1-yl]-, 1,1-dim Lapatinib Sunitinib Ibrutinib